Summary
Treatment of gastric cancer has improved substantially during the past decade. The aim of this short review is to highlight abstracts from this year’s ASCO Annual Meeting and the ASCO GI Meeting. The CRITICS trial showed no significant difference in overall survival by the addition of postoperative radiochemotherapy in the curative setting. In the palliative setting, targeting claudin could be a very promising novel treatment approach as shown by the first results of the phase II FAST trial. Many small trials show interesting results of immune checkpoint inhibitors in gastric cancer. Predictive biomarkers, however, still remain unclear. In second-line treatment of HER2-positive patients, no improvement could be shown by the use of trastuzumab emtansine in the GATSBY phase III trial.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wöll E, Devries A, Eisterer W, et al. Chemotherapy in gastric cancer. Anticancer Res. 2008;28:1213–20.
Wöll E. Perioperative therapy in gastric cancer. Memo. 2008;1:71–3.
Verheij M, Jansen EPM, Cats A, et al. A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. J Clin Oncol. 2016;34(suppl):abstr 4000.
Kang Y‑K, Shah MA, Ohtsu A, et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). J Clin Oncol. 2016;34(suppl 4 S):abstr 5.
Wöll E, Regitnig P, Eisterer W, et al. Prospective screening for human epidermal growth factor receptor 2 (HER2) positivity in patients with inoperable locally advanced or metastatic gastric or gastro-esophageal junction cancer. AGMT gastric-5. J Clin Oncol. 2016;34(suppl):abstr e15501.
Al-Batran SE, Schuler MH, Zvirbule Z, et al. FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 2016;34(suppl):abstr LBA 4001.
Janjigian YY, Bendell JC, Calvo E, et al. CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). J Clin Oncol. 2016;34((suppl):abstr 4010.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.
Diaz LA, Uram JN, Wang H, et al. Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. J Clin Oncol. 2016;34(suppl):abstr 3003.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
E. Wöll declares that he has no competing interests.
Rights and permissions
About this article
Cite this article
Wöll, E. ASCO update: gastric cancer. memo 9, 219–221 (2016). https://doi.org/10.1007/s12254-016-0293-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-016-0293-1